Evidence map›Paper›PMID 39969752›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

miRNAs in neurodegenerative diseases: from target screening to precision therapy.

Dongyi Liao, Yujie Zhang, Shuangyang Li, Hongmei Tang, Xue Bai

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dongyi LiaoDepartment of Neurology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.
Yujie ZhangDepartment of Neurology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.
Shuangyang LiDepartment of Neurology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.
Hongmei TangDepartment of Neurology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.
Xue BaiDepartment of Neurology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China. baixue@swmu.edu.cn.

Funding

Sichuan Province Science and Technology Support Program NO.2022-CXTD-05
6 · The paper itself

Abstract

miRNAs are critical for different disease development processes, including cell growth, signaling, apoptosis, cancer and neurodegenerative diseases. It has been shown that altered miRNA levels are associated with reactive oxygen species (ROS) formation and mitochondrial dysfunction. While mitochondrial dysfunction and ROS formation occur in many neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, amyotrophic lateral sclerosis, miRNAs have the potential to be diagnostic biomarkers and therapeutic targets with a high degree of specificity, which is highly relevant in neurodegenerative pathologies.This paper gives a general summary of the current expression of miRNAs in neurodegenerative diseases, including miRNAs up-regulated or down-regulated in a variety of diseases, as well as the associated factors of influence. miRNAs are more like a double-edged sword, their multi-targeted role has brought light to many diseases for which there are currently no clear therapeutic options, but at the same time, their low specificity and possible side effects on the whole body should not be ignored, therefore However, at the same time, its low specificity and possible side effects on the whole body should not be ignored, therefore, more attention should be paid to the development of miRNA therapy in terms of its high efficiency, the use of carriers, and the clarification of side effects.

Indexed as

MicroRNAsNeurodegenerative DiseasesPrecision MedicineAnimalsHumansMicroRNAsmiRNANeurodegenerative diseasesTherapy

Identifiers

PMID39969752

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.